Trial Profile

A Phase 1, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YL 201 (Primary)
Indications Nasopharyngeal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors MediLink Therapeutics

Most Recent Events

15 Nov 2024 Planned End Date changed from 1 Jul 2025 to 6 Oct 2027.
15 Nov 2024 Planned primary completion date changed from 1 Jul 2024 to 6 Apr 2027.
13 Sep 2024 According to a MediLink Therapeutics media release, results from this study were presented at the European Society for Medical Oncology (ESMO) Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com